ProBioGen News and Resources

ProBioGen has entered into an agreement with Polpharma Biologics to deliver high-performance cell line development services for an unnamed biosimilar candidate. The collaboration aims to support Polpharma’s growing biosimilar pipeline. The work will be carried out using ProBioGen’s CHO.RiGHT platform, which

ProBioGen has announced the appointment of Dr. Alfred Merz, PhD, as its new Chief Executive Officer, effective 1 April 2025. Dr. Merz previously served as the company’s Chief Operating Officer and interim CEO. Dr. Merz joined ProBioGen in 2024 from Bayer

ProBioGen and Marea Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines for cardioendocrine diseases, have announced the successful completion of a sprint project to supply clinical material for MAR002. The investigational anti-growth hormone receptor (GHR) antibody is being developed for the

ProBioGen has unveiled a new, redesigned website aimed at improving accessibility to its expanded CDMO services and proprietary technologies. The updated platform offers streamlined navigation and faster access to essential information for biotech and biopharma professionals. The new website enables

ProBioGen, a biopharmaceutical contract development and manufacturing organisation (CDMO), has announced the expansion of its manufacturing capabilities at its Berlin headquarters. The company has commissioned a new 1000L-scale GMP production line for proteins and completed the construction phase of its

Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a CDMO in biologics, vaccines and viral vectors have entered a licensing agreement to advance manufacturing capabilities for personalised cancer vaccines using ProBioGen’s

ProBioGen, the Berlin-based Contract Development & Manufacturing Organisation (CDMO) has announced a significant partnership with DIOSynVax Ltd to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever (HF) vaccine targeting diseases caused by Ebola, Marburg, and Lassa viruses. The novel vaccine, developed in